

## Physician's Orders INCLISIRAN SODIUM (LEQVIO) - ADULT, OUTPATIENT, INFUSION CENTER Page 1 to 2

Patient Name			
DOB			
MRN			
Physician			
CSN			

Defaults for orders not othe Induction (284mg every Maintenance (284mg e  Duration: # of treatments 1 year of therapy Until date:	/ 90 days for 2 doses) very 180 days)		
Anticipated Infusion Date	ICD 10 Code with Des	scription	
Height(cm)	Weight(kg) Allergies_		
Site of Service			
☐ SH Gerber	☐ SH Lemmen Holton (GR)	□ SH Pennock	□ SH United Memorial
☐ SH Helen DeVos (GR)	☐ SH Ludington	□ SH Reed City	☐ SH Zeeland
Provider Specialty			
□ Allergy/Immunology	☐ Infectious Disease	□ OB/GYN	□ Rheumatology
□ Cardiology	☐ Internal Med/Family Practice	□ Other	□ Surgery
☐ Gastroenterology	□ Nephrology	□ Otolaryngology	□ Urology
☐ Genetics	☐ Neurology	☐ Pulmonary	☐ Wound Care
pointment Requests			
	nt Request	adula appointment at most 3 days	hefore or at most 3 days after

## Provider Ordering Guidelines

Injection and possible labs

☑ ONC PROVIDER REMINDER 23

Routine, Until discontinued Starting when released Until Specified INCLISERAN SODIUM (LEQVIO) ORDERING GUIDELINES:

Missed dose: If a dose is missed by less 3 months from the usual day of administration, administer the dose as soon as possible and then resume the original schedule. If a dose is missed by more that 3 months, skip the missed dose and restart with a new dosing schedule as initial dose, then again at 3 months, and then every 6 months.

Pregnancy: Based on the mechanism of action, in utero exposure to inclisiran may cause fetal harm. Inclisiran should be discontinued as soon as pregnancy is recognized.

Lipid profile (fasting or nonfasting) before initiating treatment; fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter; low-density lipoprotein-cholesterol may be checked as early as 30 days after initiation and anytime thereafter without regard to timing of the dose.





## INCLISIRAN SODIUM (LEQVIO)- ADULT, OUTPATIENT, INFUSION CENTER *(CONTINUED)* Page 2 to 2

Patient Name	
DOB	
MRN	
Physician	
CSN	

	-

Labs				
			Interval	Duration
		Lipid Panel	□ Every 90 days	☐ Twice
		URGENT, Clinic Collect, Status: Future, Expected: S, Expires: S+365	☐ Every 180 days	□ 1 year
		Rule based evaluation for monthly pregnancy test before		
		chemotherapy cycles		
		ONC PROVIDER REMINDER 28	Every 180 days	
		Routine, Until discontinued Starting when released Until Specified	,	
		This patient does not qualify for pregnancy test based on the following criteria	:	
		* Female, aged 12 to 60 years		
		* Uterus is still intact		
If you disagree, consider adding a pregnancy test monthly prior to chemotherapy.				
		Selection Condition: Patient could NOT become pregnant		
		Beta Human Chorionic Gonadotropin (hCG) Quantitative	Every 180 days	
		URGENT, Clinic Collect, Status: Future, Expected: S, Expires: S+365 Selection Condition: Patient could become pregnant		
		Colodion Condition: 1 dilent codid become programit		
	П	Lab:		date:
			ce 🗆 1 year	
				# of Treatments
	X	ONC NURSING COMMUNICATION 25 Routine, Until discontinued Starting when released Until Specified Inclisiran (Leqvio): Contact provider if patient's planned dose is missed by mo	re than 3 months. May administer	medication at current
		visit.  The medication dosing recommendations recommend to restart a new dosing	schedule if planned dose is misse	d by more than 3
	X	months. ONC NURSING COMMUNICATION 100		
	121	Until discontinued Starting when released Until Specified		
		May Initiate IV Catheter Patency Adult Protocol		
las alsa as	4!	Tourstone		
inauc	tion	Treatment	latam al	D
		inclisiran sodium (Leqvio) 284 MG/1.5ML prefilled syringe 284	Interval Every 90	Duration 2 treatments
		mg	days	2 irealinents
		284 mg, Subcutaneous, Once, Starting when released	aayo	
		Administer subcutaenously into the abdomen, upper arm, or thigh.		
Maint		Treatment		
waint	enal	nce Treatment	Intomial	
		incliniran andium (Logvio) 294 MC/4 EML profilled assistant 294	Interval	
		inclisiran sodium (Leqvio) 284 MG/1.5ML prefilled syringe 284 mg	Every 180 days	
		284 mg, Subcutaneous, Once, Starting when released	aayo	
		Administer subcutaenously into the abdomen, upper arm, or thigh.		

**NOTE:** Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

R.N.

Sign

**ORDERED:** 

DATE

Pager#

Physician

Print

Physician

TIME



EPIC VERSION DATE: 04/19/23

TRANSCRIBED:

TIME

DATE

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

DATE

VALIDATED:

TIME

Sign